§The Drug Explorer

Search the nephrotoxic landscape

A live index of 290+ anti-cancer agents, cross-filterable by injury signature, drug class, nephron segment, severity, onset window, era, and how deeply the atlas sources it. Profiled agents open to a full citation-grounded page; the rest are catalog entries with their signature kidney signal.

Random agent

Browse the master atlas by era

Filters

Injury signature

Match the selected injury only where it is the agent’s defining (#1) renal lesion, not a secondary pattern.

Severity

Onset window

How long after dosing the signature kidney injury tends to declare — from <24 h to a genuinely variable course. Distilled from each agent's cited onset prose.

Nephron segment

Tier

146 agents carry no recorded era and are counted as Established here.

Sourcing depth

How much this atlas cites about the agent — how many references, over how many years, in what journals, whether they go beyond single case reports, whether a landmark trial is among them, how recent they are, and whether FAERS corroborates.

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

Action in reduced kidney function

The renal dose action from this atlas's label review, grouped exactly as the Renal Dosing page's “Needs a renal change” tab. “No renal-specific change identified” means our review found no label rule for the agent — not a statement that it is safe unadjusted in kidney impairment.

Drug class

Signals

Agents that are active real-world discussion topics where published renal guidance is thinnest.

Agents with a FAERS acute-kidney-injury reporting signal — ROR 95% CI lower bound > 1 on at least 50 reports. Disproportionate reporting, not a proven rate; an agent below the floor is unranked, not cleared.

Loading the catalog index…

Loading catalog…